• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Biologic Switching and Discontinuation in Patients With Rheumatoid Arthritis

Publication
Article
Drug Benefit TrendsDrug Benefit Trends Vol 22 No 4
Volume 22
Issue 4

More than half of patients with rheumatoid arthritis who were treated with a biologic discontinued treatment, and another 12% switched to at least 1 other biologic within a 2-year treatment period, according to a study led by Chureen Carter, PharmD, of Centocor Ortho Biotech Services.

More than half of patients with rheumatoid arthritis who were treated with a biologic discontinued treatment, and another 12% switched to at least 1 other biologic within a 2-year treatment period, according to a study led by Chureen Carter, PharmD, of Centocor Ortho Biotech Services.

The study included 1794 patients who were treated with biologics; 77% of the patients were women. Results showed that 1168 patients either switched treatment or discontinued treatment.1 On average, the first switch from a biologic occurred after 269 days of treatment and discontinuation occurred after 197 days of treatment. A rheumatologist prescribed more than 80% of these first switches. Of the 222 patients who switched biologics at least once, 71 switched a second time and 15 switched a third time. “Further studies are needed to investigate the reasons for biologic switching and discontinuation and the consequent impact on clinical and economic outcomes,” concluded the authors.

References:

Reference
1. Carter CT, Tang B, Buysman E, Piech CT. Two-year longitudinal study of biologic switching and discontinuation among rheumatoid arthritis patients in a health plan. Presented at: Academy of Managed Care Pharmacy 22nd Annual Meeting and Showcase; April 9-10, 2010; San Diego.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.